LONDON (Alliance News) - AstraZeneca PLC said Wednesday that its Zurampic treatment for the treatment of hyperuricemia associated with gout by the US Food and Drug Administraiton.
The company said that the drug had been approved for use in combination with a xanthine oxidase inhibitor, for patients who have not achieved target serum uric acid levels on the xanthine oxidase inhibitor alone.
"With the FDA approval of ZURAMPIC, we are pleased to offer a new treatment option for the many patients who are suffering from the effects of gout and who are not reaching the recommended serum uric acid treatment targets with the current standard of care," said Sean Bohen, executive vice president of global medicines development and chief medical officer of AstraZeneca, said in a statement.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Astrazeneca (AZN)